Blog

Latest news about encapsia

Cmed’s response to the Coronavirus (COVID-19) pandemic

Written by Cmed Technology
23 Mar 2020

Thank you for your continued loyalty and trust in Cmed and encapsia during these uncertain times. We are continuously monitoring the evolving circumstances surrounding the COVID-19 outbreak and continue to operate as normal. ~ Our highest priority is to maintain the health and safety of our people, customers, partners and suppliers while meeting our service commitments. Cmed has implemented a range of measures in line with World Health Organization guidance to minimise the risks for employees and customers. Business Continuity procedures have been in place since 10th March 2020 and the Cmed Management Committee meets on a daily basis to monitor the situation.

Despite the recent issues in many countries, we are still able to provide technology solutions for all our customers as normal. During these difficult times, encapsia continues to operate with 100% uptime. We are proud to offer industry leading software and features to give our customers the utmost flexibility to allow their studies to continue through all eventualities.

We believe we are all in this together and will continue to follow our Cmed Guiding Principle: We are one team.


Last 3 posts

Question: Your webinar presentation earlier this week was quite provocative. Could you tell us a bit more about your background? TCC: I started writing software and building computers from scratch from a very early age. My father and I ran an educational software company when I was a teenager, and then I went on to read Engineering and Computer Science at Oxford, capping this with a DPhil in AI before co-founding Cmed Technology - a lifetime writing, designing and creating enterprise platforms with a specialism and passion for the clinical trial space.
Cmed Technology announced today the encapsia Home Visit app is now available to capture and manage clinical trial data from patients at home or in the community. The app works seamlessly with all the other encapsia apps, including web EDC (Entry app) and direct data capture (esource app) to provide tremendous flexibility in the choice of data capture methods both before and during a study. This helps maintain patient participation and clinical data flow which is particularly compelling to minimize disruption during the COVID-19 pandemic as well as in the new landscape for clinical trials that is expected to follow.
The global COVID-19 crisis has fundamentally impacted the way we live our lives as well as the operation of the entire drug development community. During the early stages of the pandemic the Cmed leadership team has implemented a number of measures to ensure the safety of our employees, clients and partners, as well as ensuring the continued delivery of our CRO services and our encapsia clinical data system. Our goal has been to minimise the impact of COVID-19 on our business, our clients, investigator sites and patients.